title: Pulmonary thromboembolism in leukaemic children undergoing bone marrow transplantation.
abstract: Of 67 leukaemic children transplanted in our BMT unit 3 presented with severe acute respiratory syndrome associated with pulmonary thromboembolism (PTE) as diagnosed by scintiscan and/or angiography in the first month after BMT. Intervention with continuous positive pressure ventilation, urokinase (loading dose, then continuous infusion for 12-18 h) and heparin (continuous infusion for an average of 10 days) has been carried out successfully in two cases. In conclusion, when evaluating patients undergoing BMT and developing early pulmonary complications, PTE must be considered. The pathogenesis of PTE is still difficult to ascertain but urokinase therapy may reduce early morbidity.
authors: Department of Pediatric Haematology Oncology, Gerardo Hospital, Monza, University of Milan, Italy.
authors: C
authors: C
authors: Uderzo
authors: G
authors: G
authors: Marraro
authors: A
authors: A
authors: Riva
authors: E
authors: E
authors: Bonanomi
authors: P L
authors: PL
authors: Vaj
authors: P F
authors: PF
authors: Marchi
authors: A
authors: A
authors: Locasciulli
authors: G
authors: G
authors: Masera
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D003131:Combined Modality Therapy; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000601:surgery*; D015470:Leukemia, Myeloid, Acute / Q000601:surgery; D008297:Male; D011175:Positive-Pressure Respiration; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator